Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMCP1G9)

Drug Name
chelerythrine Drug Info
Synonyms broussonpapyrine; cheleritrine; chelerythrine hydroxide; toddalin
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
2703
ChEBI ID
CHEMBL78373
CAS Number
CAS 34316-15-9
TTD Drug ID
DMCP1G9
VARIDT Drug ID
DR00988

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DTP
DOT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Approved Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting P2X purinoceptor 7 (P2RX7)
Drug Name Drug ID Indication ICD 11 Highest Status REF
CE-224535 DMFCLT6 Arthralgia ME82 Phase 2/3 [7]
AZD9056 DMJGYPK Chronic obstructive pulmonary disease CA22 Phase 2 [8]
LY3857210 DMZO2V2 Pain MG30-MG3Z Phase 2 [9]
BIL010t DMV1EA9 Alzheimer disease 8A20 Phase 1/2 [10]
EVT 401 DMOG8IE Rheumatoid arthritis FA20 Phase 1 [11]
SGM-1019 DMDAHEL Inflammatory bowel disease DD72 Phase 1 [12]
GSK1482160 DMWDQOV Pain MG30-MG3Z Phase 1 [13]
JNJ-55308942 DM0QZJX Anhedonia MB24.2 Phase 1 [10]
JNJ-54175446 DMQ5ZVK Major depressive disorder 6A70.3 Phase 1 [14]
JNJ-479655 DMDU6GN Alzheimer disease 8A20 Clinical trial [15]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Fungal Protein kinase A (Fung ypkA)
Drug Name Drug ID Indication ICD 11 Highest Status REF
BALANOL DMDLN9E N. A. N. A. Terminated [16]
4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol DMSKJ1X Discovery agent N.A. Investigative [17]
Ro-4396686 DM5DMCH Discovery agent N.A. Investigative [18]
PMID20005102C1 DMMESBW Discovery agent N.A. Investigative [19]
[3H]cAMP DMZRQU7 Discovery agent N.A. Investigative [20]
PMID19364658C33 DMSE1C3 Discovery agent N.A. Investigative [21]
BX-912 DMZA45C Discovery agent N.A. Investigative [22]
BX-795 DMRIMLJ Discovery agent N.A. Investigative [22]
PMID21742770C1 DME3JMH Discovery agent N.A. Investigative [23]
Rp-adenosine 3',5'-cyclic monophosphothioate triethylamine (Rp-cAMPS) DM1JWGH Discovery agent N.A. Investigative [24]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting PKC-epsilon messenger RNA (PRKCE mRNA)
Drug Name Drug ID Indication ICD 11 Highest Status REF
BALANOL DMDLN9E N. A. N. A. Terminated [25]
RO-316233 DMAGLPW Discovery agent N.A. Investigative [26]
Bisindolylmaleimide-I DMOQJZC Discovery agent N.A. Investigative [27]
PROSTRATIN DM1HMJ5 Human immunodeficiency virus infection 1C62 Investigative [28]
8-Octyl-benzolactam-V9 DM4Z15M Discovery agent N.A. Investigative [29]
ISIS 7942 DMN0A1R Discovery agent N.A. Investigative [30]
ISIS 7948 DMYZE8R Discovery agent N.A. Investigative [30]
⏷ Show the Full List of 7 Drug(s)
Drug(s) Transported By Multidrug resistance-associated protein 2 (ABCC2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [31]
Methotrexate DM2TEOL Anterior urethra cancer Approved [32]
Folic Acid DMEMBJC Colorectal carcinoma Approved [33]
Fluorouracil DMUM7HZ Adenocarcinoma 2D40 Approved [34]
Dinoprostone DMTYOPD Medical abortion JA00.1Z Approved [35]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [36]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [37]
Sulfasalazine DMICA9H Irritable bowel syndrome DD91.0 Approved [38]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [39]
Oxaliplatin DMQNWRD Adenocarcinoma 2D40 Approved [40]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Bile salt export pump (ABCB11)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Glimepiride DM5FSJA Diabetic complication 5A2Y Approved [41]
Ezetimibe DM7A8TW Atherosclerosis BD40 Approved [4]
Glipizide DMZA5PQ Diabetic complication 5A2Y Approved [4]
Bosentan DMIOGBU Pulmonary arterial hypertension BB01.0 Approved [42]
Indinavir DM0T3YH Human immunodeficiency virus infection 1C62 Approved [41]
Ofloxacin DM0VQN3 Acute gonococcal cervicitis Approved [4]
Primidone DM0WX6I Epilepsy 8A60-8A68 Approved [43]
Gefitinib DM15F0X Colon adenocarcinoma Approved [41]
Drospirenone DM1A9W3 Acne vulgaris ED80 Approved [44]
Nitrendipine DM21C09 Hypertension BA00-BA04 Approved [41]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Prelamin-A/C (LMNA)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Selenium DM25CGV N. A. N. A. Approved [45]
Methotrexate DM2TEOL Anterior urethra cancer Approved [46]
Deoxycholic acid DM3GYAL Subcutaneous fat disorder EF02 Approved [47]
Quercetin DM3NC4M Obesity 5B81 Approved [48]
Hydroquinone DM6AVR4 Melasma ED60.1 Approved [49]
Marinol DM70IK5 Anorexia nervosa cachexia 6B80 Approved [50]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [51]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [52]
Demecolcine DMCZQGK Solid tumour/cancer 2A00-2F9Z Approved [53]
Ivermectin DMDBX5F Intestinal strongyloidiasis due to nematode parasite 1F6B Approved [54]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Neurotensin/neuromedin N (NTS)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Quercetin DM3NC4M Obesity 5B81 Approved [5]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [55]
Prasterone DM67VKL Chronic obstructive pulmonary disease CA22 Approved [56]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [57]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [58]
Azacitidine DMTA5OE Acute myelogenous leukaemia 2A41 Approved [59]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [60]
Fluorouracil DMUM7HZ Adenocarcinoma 2D40 Approved [61]
Bicalutamide DMZMSPF Prostate cancer 2C82.0 Approved [62]
Dihydrotestosterone DM3S8XC Prostate hyperplasia GA90 Phase 4 [56]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Spectrin alpha chain, non-erythrocytic 1 (SPTAN1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Selenium DM25CGV N. A. N. A. Approved [45]
Methotrexate DM2TEOL Anterior urethra cancer Approved [46]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [63]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [64]
Aspirin DM672AH Acute coronary syndrome BA41 Approved [65]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [57]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [52]
Ivermectin DMDBX5F Intestinal strongyloidiasis due to nematode parasite 1F6B Approved [54]
Menthol DMG2KW7 Back pain ME84.Z Approved [66]
Zoledronate DMIXC7G Adenocarcinoma 2D40 Approved [67]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Prostaglandin E synthase 3 (PTGES3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [68]
Quercetin DM3NC4M Obesity 5B81 Approved [69]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [70]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [57]
Ivermectin DMDBX5F Intestinal strongyloidiasis due to nematode parasite 1F6B Approved [54]
Cupric Sulfate DMP0NFQ Fungal infection 1F29-1F2F Approved [71]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [72]
Vorinostat DMWMPD4 Adult acute monocytic leukemia Approved [73]
Vinblastine DM5TVS3 Advanced cancer 2A00-2F9Z Approved [61]
Paclitaxel DMLB81S Breast carcinoma Approved [61]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Fungal Protein kinase A (Fung ypkA) TTYVI76 Q56921_YEREN Inhibitor [2]
P2X purinoceptor 7 (P2RX7) TT473XN P2RX7_HUMAN Modulator (allosteric modulator) [1]
PKC-epsilon messenger RNA (PRKCE mRNA) TT57MT2 KPCE_HUMAN Inhibitor [2]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Multidrug resistance-associated protein 2 (ABCC2) DTFI42L MRP2_HUMAN Substrate [3]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Bile salt export pump (ABCB11) OTRU7THO ABCBB_HUMAN Gene/Protein Processing [4]
Neurotensin/neuromedin N (NTS) OTPGDNQS NEUT_HUMAN Gene/Protein Processing [5]
Prelamin-A/C (LMNA) OT3SG7ZR LMNA_HUMAN Protein Interaction/Cellular Processes [6]
Prostaglandin E synthase 3 (PTGES3) OTPPQWI0 TEBP_HUMAN Protein Interaction/Cellular Processes [6]
Spectrin alpha chain, non-erythrocytic 1 (SPTAN1) OT6VY3A3 SPTN1_HUMAN Protein Interaction/Cellular Processes [6]

References

1 Chelerythrine and other benzophenanthridine alkaloids block the human P2X7 receptor. Br J Pharmacol. 2004 Jul;142(6):1015-9.
2 A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8.
3 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
4 Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci. 2013 Dec;136(2):328-43.
5 Protein kinase C inhibitors alter neurotensin receptor binding and function in prostate cancer PC3 cells. Regul Pept. 2008 Apr 10;147(1-3):96-109. doi: 10.1016/j.regpep.2008.01.009. Epub 2008 Feb 11.
6 An Early and Robust Activation of Caspases Heads Cells for a Regulated Form of Necrotic-like Cell Death. J Biol Chem. 2015 Aug 21;290(34):20841-20855. doi: 10.1074/jbc.M115.644179. Epub 2015 Jun 29.
7 Efficacy and safety of CE-224,535, an antagonist of P2X7 receptor, in treatment of patients with rheumatoid arthritis inadequately controlled by methotrexate. J Rheumatol. 2012 Apr;39(4):720-7.
8 Clinical pipeline report, company report or official report of AstraZeneca (2009).
9 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight
10 Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
11 Molecular and functional properties of P2X receptors ecent progress and persisting challenges. Purinergic Signal. 2012 September; 8(3): 375-417.
12 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
13 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
14 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
15 Pharmacological characterization of a novel centrally permeable P2X7 receptor antagonist: JNJ-47965567. Br J Pharmacol. 2013 Oct;170(3):624-40.
16 Joys of molecules. 2. Endeavors in chemical biology and medicinal chemistry. J Med Chem. 2005 Sep 8;48(18):5613-38. Address;
17 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9.
18 Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1950-3.
19 2,3,5-Trisubstituted pyridines as selective AKT inhibitors. Part II: Improved drug-like properties and kinase selectivity from azaindazoles. Bioorg Med Chem Lett. 2010 Jan 15;20(2):679-83.
20 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1694).
21 Identification and SAR of squarate inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK-2). Bioorg Med Chem. 2009 May 1;17(9):3342-51.
22 Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1. J Biol Chem. 2005 May 20;280(20):19867-74.
23 A Potent and Selective Quinoxalinone-Based STK33 Inhibitor Does Not Show Synthetic Lethality in KRAS-Dependent Cells. ACS Med Chem Lett. 2012 Dec 13;3(12):1034-1038.
24 Inhibition of protein kinase A activity interferes with long-term, but not short-term, memory of conditioned taste aversions. Behav Neurosci. 2002 Dec;116(6):1070-4.
25 Evaluation of differential hypoxic cytotoxicity and electrochemical studies of nitro 5-deazaflavins, Bioorg. Med. Chem. Lett. 5(18):2155-2160 (1995).
26 Synthesis of anilino-monoindolylmaleimides as potent and selective PKCbeta inhibitors. Bioorg Med Chem Lett. 2004 Oct 18;14(20):5171-4.
27 Protein kinase C epsilon regulates gamma-aminobutyrate type A receptor sensitivity to ethanol and benzodiazepines through phosphorylation of gamma2... J Biol Chem. 2007 Nov 9;282(45):33052-63.
28 A nonpromoting phorbol from the samoan medicinal plant Homalanthus nutans inhibits cell killing by HIV-1. J Med Chem. 1992 May 29;35(11):1978-86.
29 Design and synthesis of 8-octyl-benzolactam-V9, a selective activator for protein kinase C epsilon and eta. J Med Chem. 2006 May 4;49(9):2681-8.
30 US patent application no. 5,959,096, Antisense oligonucleotides against human protein kinase C.
31 Involvement of the drug transporters p glycoprotein and multidrug resistance-associated protein Mrp2 in telithromycin transport. Antimicrob Agents Chemother. 2006 Jan;50(1):80-7.
32 Dose-dependent disposition of methotrexate in Abcc2 and Abcc3 gene knockout murine models. Drug Metab Dispos. 2011 Nov;39(11):2155-61.
33 Mammalian multidrug-resistance proteins (MRPs). Essays Biochem. 2011 Sep 7;50(1):179-207.
34 Enhancing chemosensitivity in oral squamous cell carcinoma by lentivirus vector-mediated RNA interference targeting EGFR and MRP2. Oncol Lett. 2016 Sep;12(3):2107-2114.
35 Multidrug resistance associated protein 2 mediates transport of prostaglandin E2. Liver Int. 2006 Apr;26(3):362-8.
36 Lentivirus-mediated RNAi silencing targeting ABCC2 increasing the sensitivity of a human nasopharyngeal carcinoma cell line against cisplatin. J Transl Med. 2008 Oct 4;6:55.
37 Effect of acetaminophen on expression and activity of rat liver multidrug resistance-associated protein 2 and P-glycoprotein. Biochem Pharmacol. 2004 Aug 15;68(4):791-8.
38 Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G371-7.
39 Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT). Drug Metab Dispos. 2002 Apr;30(4):457-63.
40 Multidrug Resistance-Associated Protein 2 (MRP2) Mediated Transport of Oxaliplatin-Derived Platinum in Membrane Vesicles. PLoS One. 2015 Jul 1;10(7):e0130727.
41 Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci. 2010 Dec; 118(2):485-500.
42 Omics-based responses induced by bosentan in human hepatoma HepaRG cell cultures. Arch Toxicol. 2018 Jun;92(6):1939-1952.
43 Evaluating the Role of Multidrug Resistance Protein 3 (MDR3) Inhibition in Predicting Drug-Induced Liver Injury Using 125 Pharmaceuticals. Chem Res Toxicol. 2017 May 15;30(5):1219-1229. doi: 10.1021/acs.chemrestox.7b00048. Epub 2017 May 4.
44 A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicol Sci. 2013 Nov;136(1):216-41.
45 Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
46 Functional gene expression profile underlying methotrexate-induced senescence in human colon cancer cells. Tumour Biol. 2011 Oct;32(5):965-76.
47 Prevention of deoxycholate-induced gastric apoptosis by aspirin: roles of NF-kappaB and PKC signaling. J Surg Res. 2008 Mar;145(1):66-73. doi: 10.1016/j.jss.2007.04.039. Epub 2007 Jul 20.
48 Identification of biomarkers for the initiation of apoptosis in human preneoplastic colonocytes by proteome analysis. Int J Cancer. 2004 Mar 20;109(2):220-9. doi: 10.1002/ijc.11692.
49 [Differential proteomic expression in human liver cells stimulated by hydroquinone]. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi. 2006 Nov;24(11):658-61.
50 THC exposure of human iPSC neurons impacts genes associated with neuropsychiatric disorders. Transl Psychiatry. 2018 Apr 25;8(1):89. doi: 10.1038/s41398-018-0137-3.
51 Proteomics investigations of drug-induced hepatotoxicity in HepG2 cells. Toxicol Sci. 2011 Mar;120(1):109-22.
52 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
53 Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.
54 Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
55 Identification of transcriptome signatures and biomarkers specific for potential developmental toxicants inhibiting human neural crest cell migration. Arch Toxicol. 2016 Jan;90(1):159-80.
56 Comparative effects of DHEA and DHT on gene expression in human LNCaP prostate cancer cells. Anticancer Res. 2006 Sep-Oct;26(5A):3205-15.
57 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
58 The neuroprotective action of the mood stabilizing drugs lithium chloride and sodium valproate is mediated through the up-regulation of the homeodomain protein Six1. Toxicol Appl Pharmacol. 2009 Feb 15;235(1):124-34.
59 The effect of DNA methylation inhibitor 5-Aza-2'-deoxycytidine on human endometrial stromal cells. Hum Reprod. 2010 Nov;25(11):2859-69.
60 Effects of progesterone treatment on expression of genes involved in uterine quiescence. Reprod Sci. 2011 Aug;18(8):781-97.
61 Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer. 2006 Apr 1;118(7):1699-712. doi: 10.1002/ijc.21570.
62 A role for neurotensin in bicalutamide resistant prostate cancer cells. Prostate. 2007 Feb 1;67(2):190-202. doi: 10.1002/pros.20518.
63 Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
64 Gene expression profile changes in NB4 cells induced by arsenic trioxide. Acta Pharmacol Sin. 2003 Jul;24(7):646-50.
65 Effects of aspirin on metastasis-associated gene expression detected by cDNA microarray. Acta Pharmacol Sin. 2004 Oct;25(10):1327-33.
66 Repurposing L-menthol for systems medicine and cancer therapeutics? L-menthol induces apoptosis through caspase 10 and by suppressing HSP90. OMICS. 2016 Jan;20(1):53-64.
67 Zoledronate dysregulates fatty acid metabolism in renal tubular epithelial cells to induce nephrotoxicity. Arch Toxicol. 2018 Jan;92(1):469-485.
68 Minimal peroxide exposure of neuronal cells induces multifaceted adaptive responses. PLoS One. 2010 Dec 17;5(12):e14352. doi: 10.1371/journal.pone.0014352.
69 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
70 Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol. 2011 Dec;28(4):1225-54.
71 Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
72 Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
73 Proteomic analysis of liver cancer cells treated with suberonylanilide hydroxamic acid. Cancer Chemother Pharmacol. 2008 Apr;61(5):791-802.